Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

The U.S. Food and Drug Administration (FDA) has announced significant advancements in medical treatments, including the ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

Feb. 28 is Rare Disease Day and Channel 9 is spotlighting a local family working to shed light on rare diseases all year long.

About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...

Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.

MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...